A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes

References

• Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006;81:104–30
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: myelodysplastic syndromes V2.2010. 2010. Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed August 15, 2009
   Google Scholar
• Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003;120:187–200
   PubMed Web of Science ®Google Scholar
• Haferlach T, Kern W. Classification and staging of myelodysplastic syndromes. Myelodysplastic Syndromes. Berlin and Heidelberg: Springer-Verlag, 2006
   Google Scholar
• Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:1037–46
   PubMed Web of Science ®Google Scholar
• Heptinstall K. Quality of life in myelodysplastic syndromes. A special report from the Myelodysplastic Syndromes Foundation, Inc. Oncology (Williston Park) 2008;22:13–8; discussion 9
   PubMedGoogle Scholar
• Jansen AJ, Essink-Bot ML, Beckers EA, et al. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 2003;121:270–4
   PubMed Web of Science ®Google Scholar
• Steensma DP, Heptinstall KV, Johnson VM, et al. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res 2008;32:691–8
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–88
   PubMed Web of Science ®Google Scholar
• Fenaux P, Morel P, Rose C, et al. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991;77:497–501
   PubMed Web of Science ®Google Scholar
• Miller KB, Kim K, Morrison FS, et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol 1992;65:162–8
   PubMed Web of Science ®Google Scholar
• Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 2004;103:2908–13
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794–803
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–32
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. Medical care services component of consumer price index. Available at: http://data.bls.gov:8080/PDQ/outside.jsp?survey=cu. Accessed August 5, 2009
   Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
   Google Scholar
• Azacitidine Product Label. Vidaza (azacitidine for injection) for SC or IV use. Summit, NJ: Celgene Corporation, 2008. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050794s011lbl.pdf. Accessed July 15, 2009
   Google Scholar
• Decitabine Product Label. Dacogen (TM) (decitabine for injection). Bloomington, MN: MGI Pharma, inc., 2006. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021790lbl.pdf. Accessed July 30, 2009
   Google Scholar
• Centers for Medicare and Medicaid Services (CMS). Clinical diagnostic laboratory fee schedule. 2009a. Available at: http://www.cms.hhs.gov/ClinicalLabFeesched/02_clinlab.asp. Accessed August 11, 2009
   Google Scholar
• Centers for Medicare and Medicaid Services (CMS). Physician fee schedule. 2009b. Available at: http://www.cms.hhs.gov/PFSLookup/. Accessed August 5, 2009
   Google Scholar
• Goss TF, Szende A, Schaefer C, et al. Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer Control 2006;13(Suppl):17–25
   PubMedGoogle Scholar
• Deferasirox Product Label. Novartis Pharmaceutical Corporation. 2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021882s006lbl.pdf. Accessed August 6, 2009
   Google Scholar
• RED BOOK. Exjade(R) (deferasirox) tablets for oral suspension. Montvale, NJ: Thomson Healthcare, 2009
   Google Scholar
• Greenberg PL, Cosler LE, Ferro SA, et al. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J Natl Compr Canc Netw 2008;6:942–53
   PubMedGoogle Scholar
• Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002;162:1597–603
   PubMed Web of Science ®Google Scholar
• Dalziel K, Round A, Garside R, et al. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics 2005;23:515–26
   PubMed Web of Science ®Google Scholar
• Patel BB, Mohamed AN, Schiffer CA. “Acute myelogenous leukemia like” translocutions in CML blast crisis: two new cases of inv(16)/t(16;16) and a review of the literature. Leuk Res 2006;3:225–32. Epub 1 Aug 2005
   Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52–7
   PubMed Web of Science ®Google Scholar
• Celgene Corporation. AZA-001 Study Report. Summit, NJ: Celgene Corporation, 2009
   Google Scholar
• Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics 2007;25:3–6
   PubMed Web of Science ®Google Scholar
• Decitabine Product Label. Dacogen(R) (decitabine) for injection. Eisai Inc. 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021790s006lbl.pdf. Accessed on 1 April 2010.
   Google Scholar